

Sutro's Robust Pipeline of Product Candidates Demonstrates our Innovative Processes and is Intentionally Designed to Expand Patient Benefit in Areas of High Unmet Need

PROGRAM	MODALITY/TARGET	INDICATION	DISCOVERY	PRECLINICAL	PHASE 1/1B	PHASE 2/3	WORLDWIDE OR GEOGRAPHIC PARTNER
SUTRO-LED PROGRAMS							
Luveltamab tazevibulin (luvelta, STRO-002)	FolR α Antibody-Drug Conjugate (ADC)	Ovarian Cancer	<i>Fast Track Designation</i>				
		Ovarian Cancer (bevacizumab combo)					
		Endometrial Cancer					
		CBF/GLIS2 Pediatric AML	<i>Orphan Drug & Rare Pediatric Disease Designation</i>				
		Adenocarcinoma, NSCLC					
STRO-001⁽¹⁾	CD74 ADC	B-cell Malignancies	<i>Orphan Drug Designation</i>				天士力生物 TASLY BIOPHARMA (Greater China Rights)
STRO-003	ROR1 ADC	Solid Tumors & Hematological Cancers					BIONOVA Pharma 拜诺医药 (Greater China Rights)
STRO-004	Tissue Factor ADC	Solid Tumors					
PARTNER PROGRAMS							
VAX-24	24-Valent Conjugate Vaccine	Invasive Pneumococcal Disease					VAXCYTE <i>protect humankind</i>
MK-1484	Selective IL-2 Agonist	Advanced or Metastatic Solid Tumors					MERCK
Undisclosed Programs	Immunostimulatory ADCs (iADCs)	Cancers	<i>Multiple Programs</i>				astellas

1. Phase 1 dose escalation has completed in the U.S., and clinical development is ongoing in Greater China led by BioNova